Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-03-15
2005-03-15
Aulakh, Charanjit S. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S194000, C546S216000, C546S223000, C546S224000, C546S225000, C546S256000, C546S278400, C548S541000, C548S557000, C514S327000, C514S329000, C514S330000, C514S333000, C514S343000, C514S423000, C514S426000
Reexamination Certificate
active
06867221
ABSTRACT:
A cyclic amine compound represented by the following general formula (1):wherein,R1, R2and R3each independently represent a hydrogen atom or an alkoxy group;W1and W2each independently represent N or CH;X represents O, NR4, CONR4or NR4CO;R4represents a hydrogen atom, or an alkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl group; andl, m and n each represents a number of 0 or 1,a salt thereof and a hydrate thereof are provided.These compounds have inhibitory effects on both cell adhesion and cell infiltration and are useful as anti-asthmatic agents, anti-allergic agents, anti-rheumatic agents, anti-arteriosclerotic agents, anti-inflammatory agents, anti-Sjogren's syndrome agents or the like.
REFERENCES:
patent: 6395753 (2002-05-01), Kodama et al.
patent: 9-143075 (1997-06-01), None
patent: 10-67656 (1998-03-01), None
patent: 10-147568 (1998-06-01), None
patent: 10-182550 (1998-07-01), None
patent: 11-92382 (1999-04-01), None
patent: 2000-86641 (2000-03-01), None
patent: 2000-509070 (2000-07-01), None
patent: 2000-319277 (2000-11-01), None
patent: WO 0114333 (2001-03-01), None
patent: WO 0220477 (2002-03-01), None
Y. Ohkawara, et al., American Journal of Respiratory cell and Molecular Biology, vol. 12, pp. 4-12, “In Situ Expression of the Cell Adhesion Molecules in Bronchial Tissues from Asthmatics with Air Flow Limitation: In Vivo Evidence of VCAM-1/VLA-4 Interaction in Selective Eosinophil Infiltration”, 1995.
A. Sakai, et al., Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 17, No. 2, pp. 310-316, “P-Selectin and Vascular Cell Adhesion Molecule-1 are Focally Expressed in Aortas of Hypercholesterolemic Rabbits Before Intimal Accumulation of Macrophages and T Lymphocytes”, 1997.
H. Wakita, et al., Journal of Cutaneous Pathology, vol. 21, pp. 33-39, “E-Selectin and Vascular Cell Adhesion Molecule-1 as Critical Adhesion Molecules for Infiltration of T Lymphocytes and Eosinophils in Atopic Dermatitis”, 1994.
T. Satoh, et al., Eur. J. Immunol., vol. 27, pp. 85-91, “Cyclophosphamide-Induced Blood and Tissue Eosinophilia in Contact Sensitivity: Mechanism of Hapten-Induced Eosinophil Recruitment Into the Skin”, 1997.
P. P. Tak, et al., Clinical Immunology and Immunopathology, vol. 77, No. 3, pp. 236-242, “Expression of Adhesion Molecules in Early Rheumatoid Synovial Tissue”, Dec. 1995.
S. M. Albelda, et al., The FASEB Journal, vol. 8, pp. 504-512, “Adhesion Molecules and Inflammatory Injury”, May 1994.
T. A. Springer, et al., Annu. Rev. Physiol., vol. 57, pp. 827-872, “Traffic Signals on Endothelium for Lymphocyte Recirculation and Leukocyte Emigration”, 1995.
S. A. Michie, et al., Curr. Top. Microbiol. Immunol., vol. 231, pp. 65-83, “The Roles of α4-Integrins in the Development of Insulin-Dependent Diabetes Mellitus”, 1998.
N. Ebihara, et al., Current Eye Research, vol. 19, No. 1, pp. 20-25, “Anti VLA-4 Monoclonal Antibody Inhibits Eosinophil Infiltration in Allergic Conjunctivitis Model of Guinea Pig”, 1999.
S. M. Whitcup, et al., Clinical Immunology, vol. 93, No. 2, pp. 107-113, “Blocking ICAM-1 (CD54) and LFA-1 (CD11a) Inhibits Experimental Allergic Conjunctivitis”, Nov. 1999.
A. Soriano, et al., Laboratory Investigation, vol. 80, No. 10, pp. 1541-1551, “VCAM-1, But Not ICAM-1 or MAdCAM-1, Immunoblockade Ameliorates DSS-Induced Colitis in Mice”, 2000.
A. Zeidler, et al., Autoimmunity, vol. 21, pp, 245-252, “Therapeutic Effects of Antibodies Against Adhesion Molecules in Murine Collagen Type II-Induced Arthritis”, 1995.
F.Bendjelloul, et al., Clinical and Experimental Immunology, vol. 119, pp. 57-63, “Intercellular Adhesion Molecule-1 (ICAM-1) Deficiency Protects Mice Against Severe Forms of Experimentally Induced Colitis”, 2000.
W. W. Wolyniec, et al., American Journal of Respiratory Cell and Molecular Biology, vol. 18, pp. 777-785, “Reduction of Antigen-Induced Airway Hyperreactivity and Eosinophilia in ICAM-1-Deficient Mice”, 1998.
D.C. Bullard, et al., The Journal of Immunology, vol. 157, pp. 3153-3158, “Reduced Susceptibilty to Collagen-Induced Arthritis in Mice Deficient in Intercellular Adhesion Molecule-1”, 1996.
D. H. Boschelli, et al., Journal of Medicinal Chemistry, vol. 38, No. 22, pp. 4597-4614, “Inhibition of E-Selectin-, ICAM-1-, and VCAM-1-Mediated Cell Adhesion by Benzo[b]Thiophene-, Benzofuran-, Indole-, and Naphthalene-2-Carboxamides: Identification of PD 144795 as an Antiinflammaroty Agent”, 1995.
R. I. Fox, et al., Arthritis and Rheumatism, vol. 29, No. 5, pp. 577-585, “Sjögren's Syndrome: Proposed Criteria for Classification”, May 1986.
Doi Takeshi
Kodama Tatsuhiko
Kyotani Yoshinori
Nishikawa Masahiro
Oda Toshiaki
Aulakh Charanjit S.
Kowa Co. Ltd.
LandOfFree
Cyclic amine compounds and pharmaceutical composition... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cyclic amine compounds and pharmaceutical composition..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclic amine compounds and pharmaceutical composition... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3451089